REGENXBIO Securities Fraud Lawsuit
Analysis based on 31 articles · First reported Apr 01, 2026 · Last updated Apr 13, 2026
The market is negatively impacted by the class action lawsuit against REGENXBIO, as it suggests potential financial liabilities and reputational damage for the company. Investors who purchased REGENXBIO securities during the Class Period may be entitled to compensation, which could lead to a significant financial payout from REGENXBIO.
REGENXBIO, a biotechnology company, is facing multiple class action lawsuits filed by Rosen Law Firm and The Schall Law Firm. The lawsuits allege that REGENXBIO made false and misleading statements to investors between February 9, 2022, and January 27, 2026, concerning its gene therapy product candidate RGX-111 for Hurler syndrome. Specifically, the company is accused of disseminating overwhelmingly positive statements about RGX-111's trial success while concealing material adverse facts regarding its efficacy and safety, including the discovery of an intraventricular CNS tumor in a study participant. Investors who suffered losses are encouraged to join the class action before the lead plaintiff deadline of April 14, 2026. Attorneys Philip Kim and Lawrence Rosen from Rosen Law Firm, and Brian Schall from The Schall Law Firm, are involved in these efforts.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard